MXPA05010937A - Derivados de fenilalanina n-(1,3-tiazol-2-il)amino)carbonil)fenil)sulfonil) y compuestos relacionados para el tratamiento de diabetes. - Google Patents
Derivados de fenilalanina n-(1,3-tiazol-2-il)amino)carbonil)fenil)sulfonil) y compuestos relacionados para el tratamiento de diabetes.Info
- Publication number
- MXPA05010937A MXPA05010937A MXPA05010937A MXPA05010937A MXPA05010937A MX PA05010937 A MXPA05010937 A MX PA05010937A MX PA05010937 A MXPA05010937 A MX PA05010937A MX PA05010937 A MXPA05010937 A MX PA05010937A MX PA05010937 A MXPA05010937 A MX PA05010937A
- Authority
- MX
- Mexico
- Prior art keywords
- useful
- compounds
- ptp
- treatment
- phenylalkanoic acids
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 abstract 2
- 101710128896 Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/80—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
- C07C2603/24—Anthracenes; Hydrogenated anthracenes
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
- Fats And Perfumes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invencion se refiere a compuestos y sales farmaceuticamente aceptables de la formula (I), que son utiles en el tratamiento de enfermedades metabolicas relacionadas a resistencia a insulina o hiperglicemia. Estos compuestos incluyen inhibidores de proteina tirosina-fosfatasa-1B (PTP-1B), que son utiles en el tratamiento de diabetes y otras enfermedades mediadas por PTP-1B, tal como cancer, enfermedades neurodegenerativas y similares. Los compuestos de la invencion tambien son utiles en composiciones farmaceuticas y en metodos para tratar las condiciones mencionadas anteriormente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46310203P | 2003-04-14 | 2003-04-14 | |
PCT/US2004/011650 WO2004092146A2 (en) | 2003-04-14 | 2004-04-14 | N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05010937A true MXPA05010937A (es) | 2005-11-25 |
Family
ID=33300037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05010937A MXPA05010937A (es) | 2003-04-14 | 2004-04-14 | Derivados de fenilalanina n-(1,3-tiazol-2-il)amino)carbonil)fenil)sulfonil) y compuestos relacionados para el tratamiento de diabetes. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20040248937A1 (es) |
EP (1) | EP1633354B1 (es) |
JP (1) | JP2006524248A (es) |
KR (1) | KR20050121732A (es) |
CN (1) | CN1794989A (es) |
AT (1) | ATE384526T1 (es) |
AU (1) | AU2004231106A1 (es) |
BR (1) | BRPI0409447A (es) |
CA (1) | CA2522080A1 (es) |
DE (1) | DE602004011511T2 (es) |
EA (1) | EA200501607A1 (es) |
MX (1) | MXPA05010937A (es) |
NO (1) | NO20054769L (es) |
WO (1) | WO2004092146A2 (es) |
ZA (1) | ZA200509123B (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE490244T1 (de) | 2003-01-27 | 2010-12-15 | Merck Sharp & Dohme | Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren |
KR20060006953A (ko) | 2003-04-30 | 2006-01-20 | 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 | 치환된 카르복실산 |
SI1700856T1 (sl) * | 2003-12-26 | 2016-02-29 | Kyowa Hakko Kirin Co., Ltd., | Tiazolni derivat |
MY143599A (en) * | 2004-06-04 | 2011-06-15 | Merck Sharp & Dohme | Pyrazole derivatives, compositions containing such compounds and methods of use |
AU2005269792B9 (en) | 2004-07-22 | 2008-11-27 | Merck Sharp & Dohme Corp. | Substituted pyrazoles, compositions containing such compounds and methods of use |
EP1805136A1 (en) * | 2004-10-28 | 2007-07-11 | The Institutes for Pharmaceutical Discovery, LLC | Substituted phenylalkanoic acids |
EP1910303A2 (en) | 2005-07-26 | 2008-04-16 | Merck & Co., Inc. | Process for synthesizing a substituted pyrazole |
DE102006013957A1 (de) * | 2006-03-27 | 2007-10-04 | Bayer Healthcare Aktiengesellschaft | Substituierte N-Benzyl-N-phenylbenzolsulfonamide |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
GB0815781D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
GB0815784D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
GB0815782D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
CA2822017C (en) | 2010-12-23 | 2015-04-07 | Pfizer Inc. | Glucagon receptor modulators |
WO2012100734A1 (en) * | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Compounds useful as retinoid-related orphan receptor gamma modulators |
EP2673260B1 (en) | 2011-02-08 | 2016-08-17 | Pfizer Inc | Glucagon receptor modulator |
MX348131B (es) | 2011-02-25 | 2017-05-26 | Merck Sharp & Dohme | Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos. |
CA2841237C (en) | 2011-07-22 | 2016-05-10 | Pfizer Inc. | Quinolinyl glucagon receptor modulators |
US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
JP2016501203A (ja) | 2012-11-20 | 2016-01-18 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | インドールアミン2,3−ジオキシゲナーゼの阻害剤として有用な化合物 |
US9840512B2 (en) | 2013-02-22 | 2017-12-12 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014134391A1 (en) | 2013-02-28 | 2014-09-04 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
AR094929A1 (es) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
EP3126358A1 (de) | 2014-04-03 | 2017-02-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren zur behandlung von atemwegserkrankungen |
EP3126339A1 (de) | 2014-04-03 | 2017-02-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung |
CA2944617A1 (en) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof |
WO2017139414A1 (en) | 2016-02-09 | 2017-08-17 | Inventisbio Inc. | Inhibitor of indoleamine-2,3-dioxygenase (ido) |
CN106632076B (zh) * | 2016-09-20 | 2019-04-30 | 中国药科大学 | 4,6-二苯基嘧啶类化合物、其制备方法和医药用途 |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
KR102606541B1 (ko) * | 2021-04-23 | 2023-11-29 | 가천대학교 산학협력단 | 바이페닐설폰아마이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 글루카곤 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
CN115337301A (zh) * | 2022-07-22 | 2022-11-15 | 汕头大学医学院第一附属医院 | Anle138b在制备改善饮食诱导胰岛素抵抗药物中的应用 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3628335B2 (ja) * | 1996-01-23 | 2005-03-09 | 塩野義製薬株式会社 | スルホン化されたアミノ酸誘導体およびそれを含有するメタロプロティナーゼ阻害剤 |
CA2249009C (en) * | 1996-04-12 | 2003-09-16 | G.D. Searle & Co. | Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors |
US6677364B2 (en) * | 1998-04-20 | 2004-01-13 | G.D. Searle & Co. | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
DK0939627T3 (da) * | 1996-07-19 | 2003-10-13 | Tularik Inc | Pentaflourbenzensulfonamider og analoger |
PE20000127A1 (es) * | 1997-12-22 | 2000-03-14 | Novartis Ag | Derivado de bencenosulfonamida |
JP2002514633A (ja) * | 1998-05-12 | 2002-05-21 | アメリカン・ホーム・プロダクツ・コーポレイション | (2−アシルアミノチアゾール−4−イル)酢酸誘導体 |
KR20020006626A (ko) * | 1999-02-26 | 2002-01-23 | 폴락 돈나 엘. | 신규한 술폰아미드 화합물 및 그의 용도 |
DE60028791T2 (de) * | 1999-09-10 | 2007-05-24 | Novo Nordisk A/S | Modulatoren der protein tyrosin phosphatase (ptpases) |
AU782878B2 (en) * | 2000-02-05 | 2005-09-08 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
WO2001083464A1 (fr) * | 2000-04-21 | 2001-11-08 | Shionogi & Co., Ltd. | Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaire |
AU4882101A (en) * | 2000-04-28 | 2001-11-12 | Shionogi & Co., Ltd. | Mmp-12 inhibitors |
AU2001248820A1 (en) * | 2000-04-28 | 2001-11-12 | Shionogi And Co., Ltd. | Thiazole and oxazole derivatives |
EP1305285B1 (en) * | 2000-07-25 | 2007-05-16 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
US6472545B2 (en) * | 2000-08-29 | 2002-10-29 | Abbott Laboratories | Protein tyrosine phosphatase inhibitors |
AU2001292285A1 (en) * | 2000-09-29 | 2002-04-15 | Shionogi And Co., Ltd. | Thiazole or oxazole derivatives |
JP2002114768A (ja) * | 2000-10-11 | 2002-04-16 | Japan Tobacco Inc | 2−(2,5−ジハロゲン−3,4−ジヒドロキシフェニル)アゾール化合物及びそれを含有してなる医薬組成物 |
ES2337127T3 (es) * | 2000-11-02 | 2010-04-21 | Ajinomoto Co., Inc. | Nuevos derivados de pirazol y remedios contra la diabetes que los contienen. |
US7091230B2 (en) * | 2001-02-09 | 2006-08-15 | Merck & Co., Inc. | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
DE10150172A1 (de) * | 2001-10-11 | 2003-04-30 | Morphochem Ag | Neue Verbindungen, die Protein Tyrosin Phosphatase 1B (PTP-1B) inhibieren |
EP1438044A1 (en) * | 2001-10-19 | 2004-07-21 | Transtech Pharma, Inc. | Bis-heteroaryl alkanes as therapeutic agents |
WO2003035610A1 (fr) * | 2001-10-26 | 2003-05-01 | Shionogi & Co., Ltd. | Derive de sulfonamide a effet inhibiteur sur les mmp |
US7049468B2 (en) * | 2001-11-19 | 2006-05-23 | Iconix Pharmaceuticals, Inc. | Modulators of Rho C activity |
US7163952B2 (en) * | 2001-12-03 | 2007-01-16 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
ATE411279T1 (de) * | 2002-01-30 | 2008-10-15 | Amgen Inc | Arylsulfonamidobenzylverbindungen |
EP1539137B1 (en) * | 2002-07-30 | 2010-05-26 | Merck Sharp & Dohme Corp. | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
WO2004020408A1 (en) * | 2002-08-29 | 2004-03-11 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
-
2004
- 2004-04-14 US US10/824,057 patent/US20040248937A1/en not_active Abandoned
- 2004-04-14 CA CA002522080A patent/CA2522080A1/en not_active Abandoned
- 2004-04-14 DE DE602004011511T patent/DE602004011511T2/de not_active Expired - Fee Related
- 2004-04-14 KR KR1020057019661A patent/KR20050121732A/ko not_active Application Discontinuation
- 2004-04-14 AT AT04750170T patent/ATE384526T1/de not_active IP Right Cessation
- 2004-04-14 JP JP2006510073A patent/JP2006524248A/ja active Pending
- 2004-04-14 WO PCT/US2004/011650 patent/WO2004092146A2/en active IP Right Grant
- 2004-04-14 EP EP04750170A patent/EP1633354B1/en not_active Expired - Lifetime
- 2004-04-14 CN CNA2004800145768A patent/CN1794989A/zh active Pending
- 2004-04-14 BR BRPI0409447-6A patent/BRPI0409447A/pt not_active IP Right Cessation
- 2004-04-14 EA EA200501607A patent/EA200501607A1/ru unknown
- 2004-04-14 MX MXPA05010937A patent/MXPA05010937A/es unknown
- 2004-04-14 AU AU2004231106A patent/AU2004231106A1/en not_active Abandoned
-
2005
- 2005-10-17 NO NO20054769A patent/NO20054769L/no not_active Application Discontinuation
- 2005-11-11 ZA ZA200509123A patent/ZA200509123B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2522080A1 (en) | 2004-10-28 |
AU2004231106A1 (en) | 2004-10-28 |
DE602004011511T2 (de) | 2009-01-29 |
NO20054769L (no) | 2006-01-03 |
CN1794989A (zh) | 2006-06-28 |
EP1633354A2 (en) | 2006-03-15 |
EA200501607A1 (ru) | 2006-06-30 |
ZA200509123B (en) | 2007-04-25 |
WO2004092146A3 (en) | 2004-12-29 |
EP1633354B1 (en) | 2008-01-23 |
US20040248937A1 (en) | 2004-12-09 |
KR20050121732A (ko) | 2005-12-27 |
WO2004092146A2 (en) | 2004-10-28 |
ATE384526T1 (de) | 2008-02-15 |
DE602004011511D1 (de) | 2008-03-13 |
NO20054769D0 (no) | 2005-10-17 |
JP2006524248A (ja) | 2006-10-26 |
BRPI0409447A (pt) | 2006-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05010937A (es) | Derivados de fenilalanina n-(1,3-tiazol-2-il)amino)carbonil)fenil)sulfonil) y compuestos relacionados para el tratamiento de diabetes. | |
TW200630327A (en) | Substituted phenylalkanoic acids | |
MXPA05011524A (es) | Acidos carboxilicos sustituidos. | |
MXPA05011539A (es) | Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b. | |
MXPA05011537A (es) | Acidos aminocaboxilicos sustituidos. | |
MXPA05011536A (es) | Acidos carboxilicos substituidos con fenilo como inhibidores de la proteina tirosina fosfatasa-1b. | |
MXPA05011523A (es) | Heteroarilos sustituidos como inhibidores de proteinas de tirosina fosfatasas. | |
TW200630354A (en) | Substituted amino carboxylic acids | |
WO2006055708A3 (en) | Heterocycle substituted carboxylic acids for the treatment of diabetes | |
WO2006055625A3 (en) | Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors | |
WO2008074997A8 (en) | Pyridine benzamides and pyrazine benzamides used as pkd inhibitors | |
WO2008033455A3 (en) | Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors | |
EA200600414A1 (ru) | ПРОИЗВОДНЫЕ БОРОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ NF-kB И ДЕГРАДАЦИИ БЕЛКА И СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ (ВАРИАНТЫ) | |
WO2008033932A3 (en) | Biarylthiazole carboxylic acid derivatives as protein tyrosine phosphatase-ib inhibitors | |
DE602004017174D1 (de) | Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege | |
UA96441C2 (ru) | Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением | |
WO2006081230A3 (en) | 3-(indazol-5-yl)-(1,2, 4) triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer | |
WO2007125331A3 (en) | Amino-ethyl-amino-aryl (aeaa) compounds and their use | |
UA92636C2 (en) | Tetrahydro-pyrimidoazepines as modulators of trpv1 | |
WO2007089857A3 (en) | Substituted imidazole derivatives and their use as ptpase inhibitors | |
TW200631949A (en) | Substituted carboxylic acids | |
WO1999009000A3 (en) | Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis | |
WO2006138589A3 (en) | Opioid receptor ligands | |
WO2006110447A3 (en) | Pyrimidine derivatives and their use in the treatment of cancer | |
DE602004013770D1 (de) | Diagnostik- und therapie- verfahren von mit pils verbundenen krankheiten |